JP2008504289A5 - - Google Patents

Download PDF

Info

Publication number
JP2008504289A5
JP2008504289A5 JP2007518346A JP2007518346A JP2008504289A5 JP 2008504289 A5 JP2008504289 A5 JP 2008504289A5 JP 2007518346 A JP2007518346 A JP 2007518346A JP 2007518346 A JP2007518346 A JP 2007518346A JP 2008504289 A5 JP2008504289 A5 JP 2008504289A5
Authority
JP
Japan
Prior art keywords
antibody
substitution
amino acid
alanine
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007518346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008504289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/022738 external-priority patent/WO2006004663A2/en
Publication of JP2008504289A publication Critical patent/JP2008504289A/ja
Publication of JP2008504289A5 publication Critical patent/JP2008504289A5/ja
Withdrawn legal-status Critical Current

Links

JP2007518346A 2004-06-25 2005-06-24 部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加 Withdrawn JP2008504289A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58318404P 2004-06-25 2004-06-25
US62415304P 2004-11-02 2004-11-02
PCT/US2005/022738 WO2006004663A2 (en) 2004-06-25 2005-06-24 Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis

Publications (2)

Publication Number Publication Date
JP2008504289A JP2008504289A (ja) 2008-02-14
JP2008504289A5 true JP2008504289A5 (https=) 2008-07-31

Family

ID=35783288

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007518346A Withdrawn JP2008504289A (ja) 2004-06-25 2005-06-24 部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加

Country Status (6)

Country Link
US (2) US20060019342A1 (https=)
EP (1) EP1773391A4 (https=)
JP (1) JP2008504289A (https=)
AU (1) AU2005259992A1 (https=)
CA (1) CA2572133A1 (https=)
WO (1) WO2006004663A2 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584130A1 (en) * 2004-10-18 2006-04-27 Medimmune, Inc. High cell density process for growth of listeria
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
AU2006232287B2 (en) * 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
TWI422594B (zh) * 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
EP2132226B1 (en) * 2007-02-23 2019-03-27 Baylor Research Institute Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
WO2009023760A1 (en) * 2007-08-14 2009-02-19 Smithkline Beechan Corporation Novel methods and cell lines
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
ES2595638T3 (es) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI599577B (zh) * 2008-09-26 2017-09-21 Chugai Pharmaceutical Co Ltd Methods to alter the isoelectric point of antibodies using amino acid substitutions of CDR regions
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
RU2536941C2 (ru) 2009-06-10 2014-12-27 Стефен Саниг Ресерч Инститьют Лтд. Способы получения клеток, проявляющих фенотипическую пластичность
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
ES2784123T3 (es) * 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
WO2015175957A1 (en) 2014-05-16 2015-11-19 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
CN112119090B (zh) 2018-03-15 2023-01-13 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
GB201820006D0 (en) * 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
TWI335821B (en) * 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
JP2007525458A (ja) * 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体
WO2005035575A2 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies

Similar Documents

Publication Publication Date Title
JP2008504289A5 (https=)
Shi et al. Latent TGF-β structure and activation
Nemčovičová et al. Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions
FI3715372T3 (fi) Suuren affiniteetin humaaneja vasta-aineita ihmisen IL-4-reseptorille
JP7382383B2 (ja) 産生細胞株エンハンサー
Wang et al. The HMGB1 acidic tail regulates HMGB1 DNA binding specificity by a unique mechanism
JP2014527802A5 (https=)
JP2005120106A5 (https=)
Wu et al. LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3
ES2738641T3 (es) Producción de proteínas terapéuticas en células de mamífero modificadas genéticamente
JP2017509335A5 (https=)
JP2020500510A5 (https=)
Ryseck et al. Characterization of elements determining the dimerization properties of RelB and p50
Salier Chromosomal location, exon/intron organization and evolution of lipocalin genes
Herbert The ancient Z-DNA and Z-RNA specific Zα fold has evolved modern roles in immunity and transcription through the natural selection of flipons
Riechmann et al. Early protein evolution: building domains from ligand-binding polypeptide segments
Hennicke et al. Transient pentameric IgM fulfill biological function—Effect of expression host and transfection on IgM properties
KR20130088845A (ko) 인간 사이토메갈로 바이러스 감염의 검출 방법
Aguayo-Ortiz et al. Thermodynamic stability of human γD-crystallin mutants using alchemical free-energy calculations
McKown et al. Conserved regional 3′ grouping of rare codons in the coding sequence of ocular prosecretory mitogen lacritin
Chen et al. Optimization on Fc for improvement of stability and aggregation resistance
Jiang et al. Characterization of substrate binding of the WW domains in human WWP2 protein
O’Shea et al. Reliable repurposing of the antibody interactome inside the cell
JP6753143B2 (ja) ＦｃγＲＩＩａをコードするポリヌクレオチド及びＦｃγＲＩＩａの製造方法
Madhumalar et al. Dimerization of the core domain of the p53 family: a computational study